InMed Pharmaceuticals Inc.
INM
$1.34
$0.021.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -14.15% | 3.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.15% | 3.42% | |||
| Cost of Revenue | -1.52% | -32.96% | |||
| Gross Profit | -30.08% | 228.42% | |||
| SG&A Expenses | -32.01% | 69.55% | |||
| Depreciation & Amortization | 0.76% | 0.96% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.36% | -6.81% | |||
| Operating Income | 4.26% | 12.92% | |||
| Income Before Tax | 3.43% | 15.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.43% | 15.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.43% | 15.68% | |||
| EBIT | 4.26% | 12.92% | |||
| EBITDA | 4.41% | 13.26% | |||
| EPS Basic | 63.56% | 38.07% | |||
| Normalized Basic EPS | 63.56% | 38.07% | |||
| EPS Diluted | 63.56% | 38.07% | |||
| Normalized Diluted EPS | 63.56% | 38.07% | |||
| Average Basic Shares Outstanding | 165.01% | 36.15% | |||
| Average Diluted Shares Outstanding | 165.01% | 36.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||